Merck Licenses Obesity Treatment in Historic Move
Merck has taken its first step towards addressing obesity with the licensing of an oral GLP-1 candidate from China. This move marks a significant shift for the pharmaceutical giant, which has been slower to enter the market compared to some of its major peers. GLP-1, or glucagon-like peptide-1, is a class of medication that helps … Read more